1. Home
  2. DOCN vs NAMS Comparison

DOCN vs NAMS Comparison

Compare DOCN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOCN
  • NAMS
  • Stock Information
  • Founded
  • DOCN 2011
  • NAMS 2019
  • Country
  • DOCN United States
  • NAMS Netherlands
  • Employees
  • DOCN N/A
  • NAMS N/A
  • Industry
  • DOCN Retail: Computer Software & Peripheral Equipment
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOCN Technology
  • NAMS Health Care
  • Exchange
  • DOCN Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • DOCN 3.0B
  • NAMS 3.1B
  • IPO Year
  • DOCN 2021
  • NAMS N/A
  • Fundamental
  • Price
  • DOCN $45.76
  • NAMS $41.50
  • Analyst Decision
  • DOCN Buy
  • NAMS Strong Buy
  • Analyst Count
  • DOCN 13
  • NAMS 10
  • Target Price
  • DOCN $47.33
  • NAMS $44.80
  • AVG Volume (30 Days)
  • DOCN 3.0M
  • NAMS 1.0M
  • Earning Date
  • DOCN 11-05-2025
  • NAMS 11-05-2025
  • Dividend Yield
  • DOCN N/A
  • NAMS N/A
  • EPS Growth
  • DOCN 201.90
  • NAMS N/A
  • EPS
  • DOCN 2.64
  • NAMS N/A
  • Revenue
  • DOCN $863,962,000.00
  • NAMS $35,243,000.00
  • Revenue This Year
  • DOCN $16.34
  • NAMS N/A
  • Revenue Next Year
  • DOCN $14.63
  • NAMS N/A
  • P/E Ratio
  • DOCN $17.02
  • NAMS N/A
  • Revenue Growth
  • DOCN 14.20
  • NAMS 4.91
  • 52 Week Low
  • DOCN $25.45
  • NAMS $14.06
  • 52 Week High
  • DOCN $52.20
  • NAMS $42.00
  • Technical
  • Relative Strength Index (RSI)
  • DOCN 56.06
  • NAMS 65.27
  • Support Level
  • DOCN $43.67
  • NAMS $36.59
  • Resistance Level
  • DOCN $46.10
  • NAMS $40.88
  • Average True Range (ATR)
  • DOCN 2.73
  • NAMS 2.56
  • MACD
  • DOCN -0.38
  • NAMS 0.06
  • Stochastic Oscillator
  • DOCN 35.89
  • NAMS 94.13

About DOCN DigitalOcean Holdings Inc.

DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: